Test Price
2,800 AED✅ Home Collection Available
LRSAM1 Gene CMT2P Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين LRSAM1 المرتبط بـ CMT2P بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي 2026
99.9% Diagnostic Sensitivity via ISO Certified Processing
Next‑generation sequencing with Sanger confirmation, performed in a facility holding ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Premium Hospital‑Grade Home Collection
ISO‑certified cold‑chain logistics & VIP mobile phlebotomy, available 8 AM – 11 PM daily.
Telephonic Post‑Test Clinical Guidance
Expert interpretation of results in the context of your personal & family history, led by neurologists.
Direct Insurance Billing Verification
Quick confirmation via WhatsApp +971 54 548 8731 – compliant with Federal Decree‑Law No. 41 of 2024 & UAE PDPL.
الخلاصة التنفيذية (بالعربية): تحليل شامل وموثوق لجين LRSAM1 يقدّم تشخيصًا جينيًا دقيقًا لمرض شاركو-ماري-توث النوع الثاني (CMT2P) وفق أعلى معايير هيئة الصحة بدبي واللوائح الاتحادية لعام 2026. خدمة سحب منزلي مع مستشار وراثي، نتائج خلال 3-4 أسابيع، ودعم سريري بعد الفحص.
Overview
The LRSAM1 Gene CMT2P Genetic Test is a targeted next‑generation sequencing assay that identifies pathogenic mutations in the LRSAM1 gene responsible for Charcot‑Marie‑Tooth disease type 2P (CMT2P). This high‑precision diagnostic confirms the molecular basis of hereditary motor‑sensory neuropathy, enabling personalised treatment plans and family screening in the UAE.
تحليل جيني دقيق لتحديد الطفرات المسبّبة لاعتلال الأعصاب الحسي الحركي الوراثي (CMT2P) باستخدام تقنية التسلسل المتقدم.
| Feature | Our Test (LRSAM1 CMT2P NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity, deep coverage & Sanger validation | ~95% sensitivity, may miss large deletions/duplications |
| Methodology | Illumina‑based NGS + confirmatory Sanger | PCR followed by Sanger sequencing only |
| Turnaround Time | 3–4 weeks (expedited on request) | 6–8 weeks typical for custom single‑gene assays |
| Clinical Utility | Covered by top UAE insurance; DHA‑compliant | Often not reimbursed for targeted CMT2P alone |
Physician Insight & Safety Protocol
“In my practice across UAE neuropathy clinics, I’ve seen how a definitive LRSAM1 result transforms patient journeys. A positive mutation confirms CMT2P, but it does not predict the individual rate of progression; always correlate with nerve conduction studies and detailed family history. Please review your results with your neurologist before adjusting any therapy.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011 (Neurologist)
Clinical Safety Notice
⚠️ Do not discontinue prescribed medication without consulting your doctor. This test is an aid to diagnosis; it does not replace serial neurological evaluation.
Exclusion Criteria & ER Red Flags
- Not intended for acute neurological emergencies; results are not available in real‑time.
- Test cannot be performed on clotted, haemolysed, or insufficient DNA samples.
- If you experience sudden weakness, respiratory difficulty, or swallowing problems, seek immediate emergency care.
- Minors require parental/guardian consent and genetic counselling per CDS Law 2026.
Patient FAQ & Clinical Guidance
Q1: What is the purpose of the LRSAM1 gene test?
Snippet killer answer: The LRSAM1 CMT2P NGS test detects pathogenic mutations causing Charcot‑Marie‑Tooth disease type 2P, a progressive motor‑sensory neuropathy.
It is recommended when clinical findings and family history suggest autosomal dominant CMT2P. A positive result confirms the diagnosis and enables accurate genetic counselling and family risk assessment. The test is suitable for adults and, with appropriate consent, for at‑risk minors under strict UAE paediatric genetic testing regulations.
سؤال شائع (بالعربية): يكشف تحليل جين LRSAM1 عن الطفرات المسبّبة لمرض شاركو-ماري-توث النوع الثاني (CMT2P)، وهو اضطراب عصبي حسي حركي مترقٍّ. يُستخدم لتأكيد التشخيص وتوجيه الاستشارة الوراثية.
Q2: How is the test performed and what is the turnaround time?
Snippet killer answer: Our lab requires only a simple blood draw or DNA sample via DHA‑licensed home phlebotomists, with results in 3–4 weeks.
You may provide a standard whole blood sample, extracted DNA, or a single drop of blood on an FTA card. Our ISO‑certified cold‑chain logistics preserve sample integrity. The laboratory uses Illumina next‑generation sequencing with mean coverage >100×, and all pathogenic findings are confirmed by Sanger sequencing.
سؤال شائع: يتم إجراء التحليل عبر سحب عينة دم بسيطة في المنزل بوساطة فريق معتمد من هيئة الصحة بدبي، وتظهر النتائج خلال 3 إلى 4 أسابيع. العينة مقبولة أيضًا على بطاقة FTA.
Q3: Is genetic counselling included?
Snippet killer answer: A pre‑ and post‑ genetic counselling session is mandatory to interpret the pedigree and result implications, ensuring clinical relevance.
Our service mandates a structured genetic counselling appointment (in‑clinic or via telehealth) before sample collection. During this session, a certified genetic counsellor constructs a three‑generation pedigree, explains inheritance risks, and obtains informed consent as per UAE PDPL. After results are released, a second counselling session with the ordering neurologist connects the genotype to your individual care plan.
سؤال شائع: الاستشارة الوراثية قبل وبعد الفحص إلزامية، حيث يقوم مستشار وراثي معتمد برسم شجرة العائلة وتفسير النتائج بما يتوافق مع قوانين حماية البيانات في الإمارات.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians